Diabetes research and clinical practice · 2025
Hepatic steatosis with significant fibrosis is associated with preclinical carotid atherosclerosis in patients with type 1 diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Claro Maria, Viñals Clara, Giménez Marga, Perea Verónica, Granados Montserrat, Serés-Noriega Tonet, Blanco Jesús, Vinagre Irene, Mesa Alex, Milad Camila, Ayala Denisse, Solà Clara, Esmatjes Enric, Conget Ignacio, Amor Antonio J
Аннотация
AIMS: Evaluate the association between metabolic dysfunction-associated steatotic liver disease (MASLD) scores and preclinical atherosclerosis in type 1 diabetes (T1D).
METHODS: Cross-sectional study in T1D individuals without cardiovascular disease (CVD) with ≥ 1 of the following: ≥40 years, diabetic kidney disease, and/or ≥ 10 years of T1D duration with CVD risk factors. MASLD was estimated with Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), and FIB-4. Three groups were established: no steatosis, steatosis, and steatosis + fibrosis. Preclinical atherosclerosis was evaluated by carotid ultrasonography.
RESULTS: We included 679 individuals (49.8 % women, age 47.8 ± 10.7 years, T1D duration 26.9 ± 10.8 years, body mass index 26.1 ± 4.3 kg/m2). The prevalence of steatosis and steatosis + fibrosis was 45.2 % and 8.4 % by HIS and 13.7 % and 5.1 %, respectively, by FLI. Carotid plaques were correlated with steatosis/fibrosis markers (HSI + FIB-4: no steatosis, 34.6 %; steatosis, 38.1 %; steatosis + fibrosis, 64.9 %; FLI + FIB-4: 38.8 %, 50 %, and 65 %, respectively; p < 0.01 for both). In multivariate models adjusted for conventional and T1D-specific risk factors, only the steatosis + fibrosis combination by HSI was associated with atherosclerosis (OR 1.97 [1.02-3.82]) and OR 1.97 [1.01-3.84] for plaque presence and ≥ 2 plaques, respectively.
CONCLUSION: Hepatic fibrosis markers are associated with increased carotid atherosclerosis in T1D. Non-invasive MASLD scores could help identify T1D patients at higher CVD risk.
METHODS: Cross-sectional study in T1D individuals without cardiovascular disease (CVD) with ≥ 1 of the following: ≥40 years, diabetic kidney disease, and/or ≥ 10 years of T1D duration with CVD risk factors. MASLD was estimated with Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), and FIB-4. Three groups were established: no steatosis, steatosis, and steatosis + fibrosis. Preclinical atherosclerosis was evaluated by carotid ultrasonography.
RESULTS: We included 679 individuals (49.8 % women, age 47.8 ± 10.7 years, T1D duration 26.9 ± 10.8 years, body mass index 26.1 ± 4.3 kg/m2). The prevalence of steatosis and steatosis + fibrosis was 45.2 % and 8.4 % by HIS and 13.7 % and 5.1 %, respectively, by FLI. Carotid plaques were correlated with steatosis/fibrosis markers (HSI + FIB-4: no steatosis, 34.6 %; steatosis, 38.1 %; steatosis + fibrosis, 64.9 %; FLI + FIB-4: 38.8 %, 50 %, and 65 %, respectively; p < 0.01 for both). In multivariate models adjusted for conventional and T1D-specific risk factors, only the steatosis + fibrosis combination by HSI was associated with atherosclerosis (OR 1.97 [1.02-3.82]) and OR 1.97 [1.01-3.84] for plaque presence and ≥ 2 plaques, respectively.
CONCLUSION: Hepatic fibrosis markers are associated with increased carotid atherosclerosis in T1D. Non-invasive MASLD scores could help identify T1D patients at higher CVD risk.